Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy

Affiliations

¹ Drs. Cun and Lu are from the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center, Houston, Texas; email: khlu@mdanderson.org.

Editorial

Han T Cun et al. Obstet Gynecol. 2020 Mar.

. 2020 Mar;135(3):495-497.

doi: 10.1097/AOG.0000000000003733.

¹ Drs. Cun and Lu are from the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center, Houston, Texas; email: khlu@mdanderson.org.

No abstract available

Comment on

Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH. Piedimonte S, et al. Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702. Obstet Gynecol. 2020. PMID: 32028491

1. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967–75.
1. Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH. Occult tubal carcinoma after risk-reducing salpingo-oophorectomy: a systematic review. Obstet Gynecol 2020;135:498–509.
1. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 2014;32:3275–83.
1. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:1547–53.
1. Soong TR, Howitt BE, Horowitz N, Nucci MR, Crum CP. The fallopian tube, “precursor escape” and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol Oncol 2019;152:426–33.